Elvitegravir (EVG) is an integrase inhibitor used to treat HIV infection. It was developed [1] by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008.

2024年3月18日 · Uses of Elvitegravir: It is used to treat HIV infection. What do I need to tell my doctor BEFORE I take Elvitegravir? If you are allergic to elvitegravir; any part of elvitegravir; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had.

2025年1月1日 · Elvitegravir is used in combination with ritonavir and another HIV medicine (eg, atazanavir, darunavir, fosamprenavir, lopinavir, tipranavir) to treat infection caused by the human immunodeficiency virus (HIV). HIV is the virus that causes …

Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide combination is used to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).

Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.

2020年2月10日 · Based on the Department of Health and Human Services (HHS) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, elvitegravir in combination with cobicistat, tenofovir, and emtricitabine is a recommended initial treatment regimen for antiretroviral-naive HIV patients with a pre-ART CrCl>70 mL/minute.

2022年1月13日 · Elvitegravir: Elvitegravir inhibits the strand transfer activity of HIV-1 integrase (integrase strand transfer inhibitor; INSTI), an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the ...

Take elvitegravir, cobicistat, emtricitabine, and tenofovir exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Elvitegravir, cobicistat, emtricitabine, and tenofovir help to control HIV infection but do not cure it.

Since then, newer members of the INSTI class have been developed, including elvitegravir (EVG), which is in advanced clinical development and is being developed for use in both treatment-naive and treatment-experienced patients. EVG utilizes pharmacokinetic boosting to achieve adequate serum levels with once-daily dosing.

This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product contains 4 different medications: elvitegravir, cobicistat, emtricitabine, and tenofovir. Elvitegravir is known as an integrase inhibitor. Cobicistat helps elvitegravir work better.